Nutritional Outlook — AKK PROBIO Becomes First Gut-Derived Akkermansia muciniphila Strain to Clear FDA New Dietary Ingredient Review
Published: August 18, 2026
AKK PROBIO, Maypro’s Akkermansia muciniphila probiotic ingredient developed by Thankcome Biological Science and Technology, has completed the FDA’s New Dietary Ingredient (NDI) notification process as Notification #1468. According to the companies, it is the first human gut-derived Akkermansia muciniphila strain to clear this regulatory pathway.
The NDI process evaluates safety documentation, including strain characterization, manufacturing controls, and toxicological assessments. However, FDA completion should not be interpreted as confirmation of effectiveness or endorsement of specific health claims. AKK PROBIO also holds self-affirmed GRAS status for both live and pasteurized forms.
The milestone comes as research into Akkermansia muciniphila continues to expand. Independent clinical studies involving other strains have reported potential benefits related to insulin sensitivity, cholesterol, weight maintenance, and muscle strength. Results, however, have varied depending on the strain and study population.
For manufacturers, the growing evidence is promising but requires careful interpretation. Findings from one Akkermansia strain cannot automatically be applied to another, making strain-specific clinical evidence essential when evaluating ingredients such as AKK PROBIO.
